Needham Investment Management LLC Has $17.18 Million Stock Holdings in Bruker Corporation $BRKR

Needham Investment Management LLC cut its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 8.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 364,650 shares of the medical research company’s stock after selling 35,350 shares during the period. Bruker accounts for approximately 1.1% of Needham Investment Management LLC’s portfolio, making the stock its 29th biggest position. Needham Investment Management LLC’s holdings in Bruker were worth $17,179,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of BRKR. Royal Bank of Canada boosted its stake in Bruker by 8.3% in the 1st quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company’s stock worth $5,148,000 after purchasing an additional 9,501 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in Bruker in the 1st quarter valued at $262,000. Goldman Sachs Group Inc. raised its stake in Bruker by 107.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock valued at $61,162,000 after acquiring an additional 758,301 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Bruker by 2.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company’s stock worth $15,285,000 after buying an additional 9,235 shares during the last quarter. Finally, Focus Partners Wealth increased its position in Bruker by 115.0% during the 1st quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company’s stock worth $469,000 after buying an additional 6,008 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. TD Cowen boosted their price target on Bruker from $43.00 to $45.00 and gave the company a “hold” rating in a research note on Thursday, May 7th. Wolfe Research began coverage on shares of Bruker in a research note on Monday, June 1st. They issued a “peer perform” rating on the stock. Weiss Ratings upgraded shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, June 3rd. JPMorgan Chase & Co. upped their price target on shares of Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a report on Monday, June 8th. Finally, Citigroup boosted their price objective on Bruker from $40.00 to $44.00 and gave the stock a “neutral” rating in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $51.31.

Bruker Price Performance

Bruker stock opened at $56.63 on Tuesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.72 and a current ratio of 1.55. Bruker Corporation has a 52-week low of $28.53 and a 52-week high of $64.54. The stock’s 50 day moving average price is $45.01 and its two-hundred day moving average price is $43.89. The stock has a market capitalization of $8.62 billion, a price-to-earnings ratio of -235.96, a PEG ratio of 1.74 and a beta of 1.30.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The business had revenue of $823.40 million during the quarter, compared to analysts’ expectations of $795.62 million. During the same period last year, the company posted $0.47 earnings per share. The business’s quarterly revenue was up 2.7% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities analysts predict that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd will be issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, June 22nd. Bruker’s dividend payout ratio is -83.33%.

Insider Transactions at Bruker

In other news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total transaction of $79,800.00. Following the transaction, the vice president owned 128,443 shares of the company’s stock, valued at $5,124,875.70. This represents a 1.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 27.20% of the stock is owned by corporate insiders.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.